Agouron Reports Novel Anti-HIV Compounds

Important note: Information in this article was accurate in 1993. The state of the art may have changed since the publication date.

Agouron Reports Novel Anti-HIV Compounds

PR Newswire (10/20/93)

La Jolla, Calif.--At a recent New Orleans conference on antimicrobial agents and chemotherapy, Agouron Pharmaceuticals Inc. unveiled the chemical structure of a novel class of chemical compounds that may inhibit a key enzyme required for HIV replication and which may, consequently, block HIV infection of T-cells in vitro. Agouron scientist Dr. Krzysztof Appelt described how each new compound in the series fits into an "active site" on the surface of the enzyme HIV protease. The Agouron research team achieved a 60,000-fold enhancement in the potency of the first compound. That resulted in a compound called AG1284, which inactivated the enzyme with a potency equal to that of the most potent inhibitors of HIV protease. "We are encouraged and excited by the preclinical research results reported today in New Orleans," said Agouron President and CEO Peter Johnson, "but we wish to sound a general caution against premature expectations for anti-HIV agents based solely upon preclinical data."

931028
AD931958

Copyright © 1993 - Information, Inc., Bethesda, MD. The CDC National Center for HIV, STD and TB Prevention provides the following information as a public service only. Providing synopses of key scientific articles and lay media reports on HIV/AIDS, other sexually transmitted diseases and tuberculosis does not constitute CDC endorsement. This daily update also includes information from CDC and other government agencies, such as background on Morbidity and Mortality Weekly Report (MMWR) articles, fact sheets, press releases and announcements. Reproduction of this text is encouraged; however, copies may not be sold, and the CDC HIV/STD/TB Prevention News Update should be cited as the source of the information. Contact the sources of the articles abstracted below for full texts of the articles.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Elton John AIDS Foundation, the National Library of Medicine, AIDS Walk of Orange County, and donations from users like you.

Always watch for outdated information. This article first appeared in 1993. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1993. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content.